As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...
The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...
Gemma Collins has shown off a huge body transformation in the new year, revealing she's already two dress sizes smaller this ...
Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...